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1  |  INTRODUC TION
Over the last 40 years, the global prevalence of obesity in women 
has increased 2.5- fold from 6% to 15%.1 Over a similar timeframe, 
the prevalence of obesity- related co- morbidities, of which there 
are >50 that collectively account for a substantial global health and 
socio- economic burden,2- 4 has increased commensurately. The de-
velopment of many obesity- related conditions is mediated through 
the deleterious effects of insulin resistance (a consequence of 
weight gain) or compensatory hyperinsulinaemia, and its associated 
metabolic dysfunction.5 These include features of the metabolic 
syndrome (type 2 diabetes mellitus [T2D], dyslipidaemia and hy-
pertension) and obesity- related malignancies such as endometrial 
carcinoma.6
Polycystic ovary syndrome (PCOS) is an important and highly 
prevalent obesity- related comorbidity,7 that develops in girls and 
women who are genetically predisposed to its development.8- 11 
PCOS affects between 6%- 10% of reproductive- age women12- 15 and 
often develops during adolescence.3 PCOS manifests with the typ-
ical clinical features of hyperandrogenism (including acne, hirsutism 
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Abstract
The increased global prevalence of obesity over the last 40- years has driven a rise 
in prevalence of obesity- related co- morbidities, including polycystic ovary syndrome 
(PCOS). On a background of genetic susceptibility, PCOS often becomes clinically 
manifest following weight gain, commonly during adolescence. A common endo-
crinopathy affecting between 6%- 10% of reproductive- age women, PCOS presents 
with the cardinal features of hyperandrogenism, reproductive and metabolic dysfunc-
tion. PCOS associates with insulin resistance, independently of (but amplified by) obe-
sity. Insulin resistance in PCOS is characterized by abnormal post- receptor signalling 
within the phosphatidylinositol- kinase (PI3- K) pathway. Multiple factors (including 
most notably, weight gain) contribute towards the severity of insulin resistance in 
PCOS. Compensatory hyperinsulinaemia ensues, resulting in over- stimulation of the 
(intact) post- receptor mitogen- activated protein kinase (MAP- K) insulin pathway, with 
consequent implications for steroidogenesis and ovarian function. In this concise re-
view, we explore the effects of weight gain and obesity on the pathogenesis of PCOS 
from the perspective of its three cardinal features of hyperandrogenism, reproductive 
and metabolic dysfunction, with a focus on the central mediating role of the insulin 
pathway. We also consider key lifestyle strategies for the effective management of 
obese and overweight women with PCOS.
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and male- pattern alopecia) and reproductive dysfunction (including 
oligo- amenorrhoea and associated sub- fertility).16 Although not a 
constituent of its diagnostic criteria,17 metabolic dysfunction also 
often forms an important component of the clinical presentation 
of PCOS. There are also characteristic biochemical and radiological 
features.18
The close association between obesity and PCOS is supported 
by epidemiological data, revealing that between 38%- 88% of women 
with PCOS are either overweight or obese.3,19,20 A meta- analysis of 
relevant studies reported in the literature showed that women with 
obesity had an odds ratio of 2.77 for the development of PCOS com-
pared with their non- obese counterparts.21 Furthermore, data from 
the Northern Finland Birth Cohort (NFBC) 1966 reveal associations 
between Body Mass Index (BMI) and features of PCOS at all ages,22 
and between an early rebound of adiposity in childhood and the sub-
sequent development of PCOS (and obesity) in adulthood.23 Such 
epidemiological data that support an association between obesity 
and PCOS are further corroborated by evidence from genetics stud-
ies that suggest an important role for gene variants implicated in the 
determination of fat mass (such as variants within the FTO gene24- 29), 
as a mechanistic link for the development of PCOS. A genome- wide 
meta- analysis of PCOS also confirmed evidence for a shared genetic 
architecture between obesity, various metabolic traits and PCOS.30 
Such genetic effects on fat mass are likely to contribute towards the 
overall heritability of PCOS.5
Following an overview of insulin resistance in PCOS, we explore 
the complex pathogenesis of PCOS, including its mediation through 
the obesity- related insulin pathway,3 from the perspective of each 
of its main features: metabolic dysfunction, hyperandrogenism and 
reproductive dysfunction. We also consider key lifestyle strategies 
for the effective management of obese and overweight women with 
PCOS.
1.1  |  Insulin resistance in PCOS
Insulin resistance is present in many, if not most, women with 
PCOS.31- 33 Although the mechanism of insulin resistance in PCOS 
remains incompletely understood, the underlying defect is reported 
to occur within the post- receptor phosphatidylinositol 3- kinase (PI3- 
K) insulin pathway that mediates the metabolic effects of insulin.3 
Other factors may also contribute towards the establishment of in-
sulin resistance in women with PCOS. These include increased levels 
of plasma testosterone (both in adulthood and prenatally, with evi-
dence of the latter from an ovine model of PCOS34) and enhanced 
sensitivity of the androgen receptor (determined by the androgen 
receptor CAG repeat number).35 Furthermore, suppressed levels 
of serum adiponectin in women with PCOS compared with BMI- 
matched control women (demonstrated in a large meta- analysis on 
>3400 subjects) may further contribute towards the establishment 
of insulin resistance in PCOS.36 The role of high molecular weight 
adiponectin in PCOS remains incompletely understood 37 and should 
form a focus for future research as there may be implications for 
therapy, as suggested by a recent study in a rodent model of PCOS.38
The severity of insulin resistance in women with PCOS is in-
creased by subsequent weight gain,3,39 possibly mediated through 
inflammatory pathways.40 Similar to the insulin resistance that char-
acterize T2D and PCOS, only the PI3- K post- receptor insulin path-
way becomes resistant to the effects of insulin following weight gain 
and obesity.41 Perhaps the umbrella term ‘insulin resistance’ should 
be replaced by the more descriptive term ‘metabolic insulin resis-
tance’,41 that results from selective dysfunction of the PI3- K post- 
receptor insulin pathway in PCOS that is augmented commensurately 
with weight gain. Importantly, in both PCOS and obesity, the other 
main post- receptor insulin pathway, the ‘mitogen- activated protein 
kinase’ (MAP- K) pathway remains unaffected.3,42 Compensatory hy-
perinsulinaemia ensues in an unsuccessful attempt to overcome the 
selective metabolic dysfunction stemming from the defective PI3- K 
insulin pathway.41 The resulting preferential activation of the MAP- K 
post- receptor insulin pathway results in atherogenic, steroidogenic 
and mitogenic effects.43 Furthermore, the preserved MAP- K insulin 
pathway confers much of the pleiotropic and deleterious effects of 
hyperinsulinaemia in obese women with PCOS that result in much of 
the hyperandrogenic and reproductive dysfunction that typify this 
condition (summarized in Figure 1).3,44
1.2  |  The role of weight gain in the pathogenesis of 
metabolic dysfunction in PCOS
Although PCOS is associated with insulin resistance independently 
of obesity,3 obesity greatly increases its prevalence and degree. 
Accordingly, PCOS also confers an increased risk for the develop-
ment of T2D,7 impaired glucose tolerance,45 obstructive sleep ap-
noea (OSA),46 dyslipidaemia and non- alcoholic fatty liver disease 
(NAFLD).47 Such exposure to enhanced overall cardiometabolic risk 
likely translates into increased cardiovascular events and perhaps 
even premature mortality post- menopause. However, evidence to 
confirm such a hypothesis is currently deficient due to a lack of pro-
spective and longer- term studies in women with PCOS that extend 
into post- menopause. This should form a focus for future research 
and would provide much insight into the temporal progression and 
metabolic legacy of PCOS beyond menopause, particularly regard-
ing cardiometabolic risk and cardiovascular events and outcomes.
The hyperandrogenic and reproductive features of PCOS are 
driven primarily through the effects of compensatory hyperinsuli-
naemia on the ovary.48 Conversely, the metabolic dysfunction and 
cardiometabolic risk that characterizes PCOS stems from a defective 
PI3- K post- receptor insulin pathway, the severity of which is influ-
enced by body fat mass.3,49,50 Given that the severity of compen-
satory hyperinsulinaemia associates with the defectiveness of the 
PI3- K post- receptor insulin pathway, this provides a hypothetical 
direct link between the severity of metabolic dysfunction and the 
hyperandrogenic and reproductive features of PCOS.
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The clinical and biochemical phenotype of PCOS is heteroge-
neous and that has a bearing on the manifestation of metabolic 
dysfunction. Studies on large and well- phenotyped cohorts have 
demonstrated confinement of insulin resistance (and associated 
features of the metabolic syndrome) to the subgroup of PCOS that 
manifest both hyperandrogenic and reproductive features.17,51 
Furthermore, the Rotterdam- defined diagnostic phenotypic sub-
groups with either hyperandrogenism or reproductive dysfunction 
alone had insulin sensitivity that was equivalent to that of women 
in BMI- matched control groups.17,51,52 We also showed differences 
in BMI between the Rotterdam- defined phenotypic subgroups, 
those women with both hyperandrogenic and reproductive features 
having a significantly higher BMI than those women in the other 
subgroups.17,52
In addition to weight gain, androgenicity and serum adiponectin 
levels, as outlined earlier, and many other factors may also influence 
the severity of insulin resistance and overall metabolic dysfunction 
in women with PCOS:
1.2.1  |  Adipokines
Adipokines, by definition, are cytokines secreted by adipose tissue. 
Accordingly, serum levels of adipokines usually associate with body 
fat mass and severity of obesity. Many adipokines influence insu-
lin sensitivity and overall cardiometabolic risk. One such adipokine, 
visfatin, plays a role in pathways that involve metabolism, inflamma-
tion and insulin sensitivity.44,53 Serum levels of visfatin are higher 
in women with PCOS than in control women.53- 56 Elevated levels 
of serum visfatin in PCOS may therefore contribute towards insulin 
resistance and metabolic dysfunction. Reports on other adipokines 
in PCOS from the literature have produced mixed results. It is possi-
ble that retinol binding protein 4 mediates some effects of increased 
body fat mass on the development of PCOS through effects on in-
sulin sensitivity.37,57 However, adipocyte fatty acid- binding protein 
does not appear to associate with either the metabolic or hyper-
androgenic features of PCOS.58 In future studies, it may be help-
ful to focus on the underlying mechanisms that mediate the effects 
of serum adipokines on the PI3- K post- receptor insulin pathway in 
PCOS, and the subsequent development of this condition.
1.2.2  |  Obstructive sleep apnoea (OSA)
OSA is another obesity- related condition,59 characterized by re-
current episodes of upper airway obstruction and intermittent hy-
poxia during sleep, with consequent impairment in sleep quality.60 
Similarly to PCOS, OSA also associates independently with insulin 
resistance even following adjustments for BMI,31- 33,61 possibly me-
diated via associated changes in serum adipokines, catecholamines 
and cortisol.62
Although, overall, OSA occurs more commonly in men,63 women 
with PCOS are also at greater risk of developing OSA compared with 
BMI- and age- matched control women.64 Women with PCOS have 
a 2- fold higher risk of developing OSA compared to women without 
PCOS matched for BMI and age, based on data from a large lon-
gitudinal study.65 It is possible that mediation of such an increased 
risk of OSA in PCOS occurs through the typical hormonal changes 
of PCOS. For example, testosterone influences apnoeic threshold 
and breathing instability during sleep.66 Furthermore, a relative 
F I G U R E  1  Overview of the role of 
the post- receptor insulin pathways in 
the mediation of hyperandrogenism, 
reproductive and metabolic dysfunction 
in women with PCOS. MAP- K, 
Mitogen- Activated Protein Kinase; 
OSA, Obstructive Sleep Apnoea; PI3- K, 
Phosphatidylinositol 3- Kinase
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lack of serum progesterone in anovulatory PCOS 3 may predispose 
to increased upper airway resistance through reducing the activity 
of the upper airway dilator muscles.67 Finally, obesity (particularly 
visceral fat content) contributes towards the risk of OSA in women 
with PCOS.68,69 Due to the combined independent associations be-
tween obesity, PCOS and OSA with insulin resistance and metabolic 
dysfunction, it is perhaps not surprising that obese women with both 
PCOS and OSA have marked insulin resistance, and a particularly 
high risk of developing T2D and metabolic syndrome.70 Based on the 
evidence outlined here, it is important to screen proactively for OSA 
(eg. through Epworth questionnaires) at least yearly in obese women 
with PCOS, given the increased risk of OSA in this population group, 
its implications for metabolic health, its treatability through weight 
loss strategies and the application of continuous positive airways 
pressure (CPAP) therapy.
1.2.3  |  Visceral and hepatic fat
Mediation of the association between weight gain and insulin resist-
ance occurs primarily through increased amounts of visceral and 
hepatic fat.71 Similarly, it is likely that in women with PCOS, there 
is enhancement of insulin resistance and metabolic dysfunction 
through visceral and hepatic fat. NAFLD occurs commonly in obese 
women with PCOS, supporting a role for hepatic fat.72 This also pro-
motes regular monitoring of liver function through biochemical and/
or radiological techniques in obese women with PCOS. However, 
the role of visceral fat in PCOS is more contentious. Although early 
studies, using techniques such as ultrasound, suggested a prepon-
derance of visceral fat in women with PCOS, more recently studies 
have utilized magnetic resonance imaging (MRI) and cast doubt on 
this hypothesis. We used MRI to compare visceral fat depots (meas-
ured through axial cross- sectional areas) between BMI- and fat 
mass- matched pairs of women with PCOS and controls, and dem-
onstrated equivalent visceral areas between the two groups, despite 
differences in insulin sensitivity.69 Subsequent MRI- based studies 
provided confirmative data.73,74 However, a lack of visceral fat pre-
ponderance in PCOS in no way diminishes the importance of visceral 
fat as a contributor to insulin resistance in this condition, due to a 
positive correlation between total body and visceral fat mass de-
pots in women, regardless of their PCOS status.44,69,75 Therefore, 
increased volume of visceral fat, associated with overall weight gain 
and obesity, is likely to contribute to insulin resistance and metabolic 
dysfunction in PCOS.
1.3  |  The role of weight gain in the pathogenesis of 
hyperandrogenism in PCOS
Hyperandrogenism in PCOS encompasses clinical and/or bio-
chemical features. Most commonly, the clinical manifestations of 
hyperandrogenism include hirsutism, acne and androgenic alo-
pecia. Biochemically, hyperandrogenaemia of PCOS stems from 
over- production of androgens, principally from the ovary but with a 
variable contribution from adrenal glands. It includes raised plasma 
levels of total testosterone, androstenedione and dehydroepian-
drostenedione sulphate (DHEAS). In addition, a raised free androgen 
index also typifies PCOS, resulting from suppression of sex hormone 
binding globulin (SHBG) in the presence of raised or normal plasma 
levels of testosterone. Compensatory hyperinsulinaemia in PCOS, 
through its stimulatory effects on the fully functional post- receptor 
MAP- K insulin pathway, plays an important role in the establishment 
of hyperandrogenaemia that in turn underlies the clinical features of 
hyperandrogenism, with multiple pathogenic pathways implicated:
1.3.1  |  Stimulatory effects of insulin on the 
ovarian theca cell – insulin as a co- gonadotrophin
Insulin acts directly as a gonadotrophin within the ovarian theca 
cells, thereby driving ovarian steroidogenesis through the hyper-
insulinaemic effects on the MAP- K insulin pathway. Within the 
ovarian theca cells, there is synergism of insulin with luteinizing hor-
mone (LH) through the activation of cytochrome P450 17α (CYP17 
or P450c17α), a key enzyme in ovarian androgen biosynthesis.76- 78 
Ovarian androgen biosynthesis in PCOS may be further enhanced 
through suppressed levels of serum adiponectin,36,44 given the 
known inhibitory effects of adiponectin on ovarian androgen pro-
duction.79 In support of this hypothesis, a study in pubertal girls with 
type 1 diabetes mellitus showed an inverse correlation between lev-
els of serum adiponectin and testosterone and ovarian volume.80
1.3.2  |  Stimulatory effects of insulin on the 
adrenal cortex
Insulin stimulates steroidogenesis within the adrenal cortex,3 medi-
ated through effects on adrenal P450c17α activity.81 This drives the 
production of adrenal androgens, including androstenedione and 
DHEAS that complements the hyperandrogenic effects of enhanced 
ovarian biosynthesis.
1.3.3  |  Suppressive effects of insulin on hepatic 
production of sex hormone binding globulin (SHBG)
Insulin suppresses the hepatic production of SHBG,82,83 thereby ac-
counting for suppressed serum levels of SHBG in PCOS. A decrease 
in serum SHBG levels leads to a commensurate increase in the free 
androgen index (a measure of free, or ‘biologically available’ andro-
gens), and therefore overall androgenicity. In a recent systematic re-
view and meta- analysis of the literature, it was concluded that serum 
levels of SHBG may provide a useful biomarker in the management of 
PCOS,84 particularly in the assessment of metabolic status. Indeed, 
suppressed serum levels of SHBG associate with a less favourable 
cardiovascular disease risk profile, albeit in men.85
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1.3.4  |  Stimulatory effects of insulin on the pituitary 
release of LH
Rodent- based in vitro models have demonstrated stimulatory effects 
of insulin at the level of the pituitary gonadotrophin- releasing cells, 
with enhancement of the LH pulse amplitude.32,86 However, the pitui-
tary effects of hyperinsulinaemia in PCOS remain contentious. In one 
study, it was demonstrated that in women with PCOS, serum LH lev-
els, LH pulse frequency and amplitude and gonadotrophin response 
to gonadotrophin- releasing hormone (GnRH) were not influenced by 
the administration of pioglitazone (an insulin- sensitizing drug), either 
with or without a concurrent infusion of insulin, casting doubt on an 
important role of hyperinsulinaemia on LH release in PCOS.87
Weight gain also drives hyperandrogenaemia in women with PCOS 
through mechanisms that do not directly implicate hyperinsulinaemia 
or insulin resistance. In a large study of urinary steroid profiles in PCOS 
(PCOS: n = 178; BMI- matched control women: n = 100), an associa-
tion between PCOS status and enhanced 5- α reductase activity was 
found.88 In this study, 5- α reductase activity was also associated with 
adiposity in both groups,88 possibly through increased enzyme expres-
sion within adipose tissue, although there may be other explanations 
given that 5- α reductase is expressed in multiple tissues, including in 
the dermis.89 We hypothesize that enhanced 5- α reductase activity 
in women with PCOS drives hyperandrogenaemia through two main 
mechanisms. Firstly, increased 5- α reductase activity enhances the 
conversion of cortisol into its breakdown products with associated re-
duction in the negative feedback effect of cortisol at the hypothalamo- 
pituitary unit, and consequent activation of the hypothalamo- pituitary 
adrenal (HPA) axis and further enhancement of adrenal androgen bio-
synthesis. (To corroborate this hypothesis, our data indeed confirmed 
enhanced HPA axis activity in women with PCOS compared with BMI- 
matched control women88). Secondly, increased 5- α reductase activity 
also enhances the conversion of testosterone into the more potent an-
drogen, 5- dihydroxytestosterone (5- DHT). The 5- α reductase driven 
increased biosynthesis of 5- DHT may therefore further enhance the 
hyperandrogenic features of PCOS.
1.4  |  The role of weight gain in the pathogenesis of 
reproductive dysfunction in PCOS
The reproductive features of PCOS consist primarily of oligo- 
amenorrhoea and impaired fertility. Underlying these clinical 
manifestations is abnormal ovarian follicle development leading to 
infrequent or absent ovulation.48,90
Hyperinsulinaemia in PCOS contributes to premature granulosa 
cell luteinization.91,92 This combined with enhanced ovarian andro-
gen production results in subsequent arrest of cell proliferation and 
follicular growth.90 Furthermore, small antral follicles in PCOS over-
express LH receptors,93,94 and steroid production shifts towards a 
preponderance of progesterone (rather than estradiol).90,91 These 
complex underlying mechanisms translate into arrest of follicle 
development in PCOS at the pre- antral phase,48,94,95 that in turn 
manifest in oligo- anovulation, oligo- amenorrhoea and impaired 
fertility. Further rodent- based evidence for an important role of hy-
perinsulinaemia in impaired follicular development stems from the 
observation of upregulation of LH receptor expression in cultured 
mouse cumulus- oocyte complexes with reduced blastocyst devel-
opment, in response to exposure to insulin and follicle stimulating 
hormone (FSH).90,96 Interestingly, there may also be a role for in-
creased intra- ovarian 5α- reductase activity in PCOS in the patho-
genesis of reproductive dysfunction, given the inhibitory effects of 
5- DHT on granulosa cell aromatase activity, and subsequent harmful 
effects of limited estradiol production on oocytes.90,97,98
Having explored the mechanisms whereby weight gain and obe-
sity contribute to the pathogenesis of PCOS from the perspective 
of its three cardinal features of metabolic dysfunction, hyperandro-
genism and reproductive dysfunction, including the central role of 
the insulin pathway (summarized in Figure 2), we now turn to some 
key aspects of management of PCOS.
1.5  |  The role of lifestyle modification in the 
effective management of PCOS
Given the central role of the dysfunctional insulin signalling in the 
pathogenesis of PCOS, it is perhaps not surprising that the most ef-
fective management strategies for this condition include attempts to 
improve function of this pathway, including most notably through ef-
fective and sustained weight loss. Calorie restriction and weight loss 
result in a reduction of hyperinsulinaemia and improvement in the 
hyperandrogenic and reproductive features of PCOS. Indeed, even 
modest weight loss of around 5% can result in clinically meaningful 
improvements in the metabolic, hyperandrogenic and reproductive 
features of PCOS (including restoration of ovulation, menstrual cy-
clicity and fertility).3,99- 101
It is beyond the scope of this concise review to provide an ex-
haustive exposition of the pharmacological management of PCOS, 
covered in detail elsewhere.102 Here we focus on lifestyle manage-
ment strategies, with great potential for improving the clinical out-
come for women and girls with PCOS.
1.5.1  |  Physical exercise
Regardless of PCOS status or degree of insulin resistance, physi-
cal exercise improves insulin sensitivity.103 Furthermore, physical 
training, through optimization of glucose transport and metabolism, 
potentiates the effects of physical exercise on insulin sensitivity.103 
Therefore, engagement in regular physical exercise, regardless of 
PCOS status, reduces overall cardiovascular risk. This is particularly 
desirable in obese women with PCOS given the frequent promi-
nence of both metabolic dysfunction and inherent insulin resistance. 
Optimized physical activity often complements dietary change as an 
effective means of weight loss through lifestyle change. Importantly 
however, the beneficial effects of physical activity on insulin 
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sensitivity often stem from the activity itself (and combined avoid-
ance of sedentariness), rather than necessarily resulting from any 
attendant weight loss, (although any resultant weight loss would be 
expected to further improve insulin sensitivity).
In women with PCOS, aerobic exercise can also improve reproduc-
tive function, including normalized menstrual cyclicity104,105 and ovu-
lation.105,106 However, despite the clear benefits of physical activity 
and exercise on reproductive function in women with PCOS, one ca-
veat is that excessive exercise can have the opposite effect. Published 
data suggest that engagement in physical exercise for >60 minutes 
per day in women with PCOS can actually increase the risk of anovu-
lation.107 Conversely, engagement in physical exercise for 30- 60 min-
utes per day reduces the risk of anovulatory infertility.107 Therefore, 
as a means of improving insulin sensitivity, reproductive health and 
overall metabolic health, women with PCOS should be encouraged 
to engage in regular physical exercise for between 30- 60 minutes 
per day, but to avoid excessive exercise. Finally, it is important to em-
phasize the importance of physical activity as a means of reducing 
sedentariness, given the association of the latter with poorer overall 
metabolic health, cardiorespiratory fitness and liver fat.108
1.5.2  |  Dietary modification
Dietary modification forms a key component of lifestyle implemen-
tation for successful weight loss. However, there remains much 
controversy and incomplete understanding regarding the details of 
optimal dietary change for the achievement of weight loss in any 
scenario. In a recent review of the literature on the effects of di-
etary modification on weight loss, there was no evidence to support 
any single dietary scheme (including food group, nutrient or dietary 
pattern) as being more efficacious than other options.109 There was 
also an identified gap in the literature regarding the effect of dietary 
modifications on weight maintenance, with most studies reporting 
the effects of weight loss regimes.109
In women with PCOS, it is important to advocate the adoption of 
a healthy and balanced diet to optimize overall health and wellbeing, 
although dietary modification is often encouraged to achieve weight 
loss. Unfortunately, as with diets in general, there is contention re-
garding the optimal dietary composition to facilitate weight loss in 
obese women with PCOS. A comprehensive review of the literature 
on the weight- losing effects of various diets revealed subtle differ-
ences.110 Monounsaturated fat- enriched and low- glycaemic index 
diets are associated with greater weight loss and improved men-
strual regularity, respectively.110 Furthermore, low- carbohydrate 
or low- glycaemic index diets are associated with greater reductions 
in insulin resistance and an improvement in lipid profile.110 A high- 
protein diet is associated with reduced depression and improved 
self- esteem. Finally, high- carbohydrate diets are linked with in-
creased free androgen index.110 Therefore, based on the available 
evidence, perhaps the best dietary advice we can provide obese 
women with PCOS is to reduce their overall caloric intake, whilst 
maintaining a healthy, balanced and nutritionally replete diet. Use of 
low- carbohydrate or low- glycaemic index diets appears particularly 
helpful, whilst maintaining high intake of protein. Finally, a diet rich 
in dietary fibre can also contribute towards successful weight loss, in 
F I G U R E  2  Overview of the role of obesity and insulin resistance in the pathogenesis of PCOS. 5- DHT, 5- Dihydroxytestosterone; DHEAS, 
Dehydroepiandrostenedione sulphate; HPA, Hypothalamo- pituitary adrenal; NAFLD, Non- alcoholic fatty liver disease; OSA, Obstructive 
Sleep Apnoea; Pit, Pituitary gland; SHBG, Sex Hormone Binding Globulin; T, Testosterone
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addition to conferring numerous other health benefits through the 
establishment and nurture of a diverse gut microbiota.111
1.5.3  |  Optimization of sleep
It is hard to overstate the importance of sleep for normal physiologi-
cal functioning. Sleep deprivation adversely affects nearly every as-
pect of mental and emotional functioning, and impacts negatively on 
physiology generally, including promotion of metabolic dysfunction, 
inflammation and importantly, insulin resistance.112 In addition to 
being an independent risk factor for insulin resistance, sleep depri-
vation also associates with increased BMI113 and results in changes 
to appetite and increased caloric ingestion. In one study, sleep dep-
rivation for just 2 nights resulted in enhanced appetite and increased 
caloric ingestion, with a preference for sweet and fatty foods. There 
were also changes in serum levels of the appetite hormones, includ-
ing ghrelin (increased) and leptin (decreased).114,115
The strong association between PCOS and OSA, mediated through 
effects on insulin resistance,64 provides a rationale for exploring the 
effects of treatment of OSA on the clinical features of PCOS. Indeed, 
one study explored the effects of treatment with CPAP therapy in 
a cohort of women with PCOS and OSA demonstrating that this 
therapy was effective at alleviating insulin resistance, and partially 
reversed metabolic dysfunction.116 Furthermore, bariatric surgery is 
an excellent treatment option for OSA, with a resolution rate of 85% 
based on a large systematic review of the literature.117 Key learning 
points from the literature include improved awareness of the strong 
link between PCOS and OSA, and the independent effect of OSA on 
insulin resistance and the severity of the clinical and metabolic fea-
tures of PCOS. Therefore, we should adopt a proactive approach to 
screening for OSA in obese women with PCOS. Screening for OSA 
should form an annual assessment in obese women with PCOS, and 
we should have a low threshold for requesting polysomnography and 
focused sleep assessment once there is a clinical suspicion of OSA. A 
diagnosis of OSA promotes candidacy for bariatric surgery in obese 
women with PCOS, given the confirmed efficacy of this treatment 
modality. Finally, OSA in women with PCOS often requires effective 
treatment with CPAP therapy from specialist teams.
In addition to the effective diagnosis and management of OSA in 
obese women with PCOS, it is also important to ensure optimization 
of sleep sufficiency. The success of implemented lifestyle measures 
(including dietary modification) to lose weight appear to depend on 
a prerequisite of sleep sufficiency.118 In one study, a 2- week inter-
vention of individualized counselling on sleep hygiene in overweight 
participants enabled a sleep duration of 7- 8 hours per night (com-
pared with their usual pre- study <6.5 hours of sleep per night). This 
intervention resulted in a 14% reduction in overall appetite ratings 
(particularly for sweet and salty foods), a 7% increase in daytime 
activity and improved sleepiness.119 Based on such evidence, sleep 
sufficiency forms a pillar of lifestyle management for obesity, par-
ticularly in women with PCOS. The ability to modify one's diet and 
engage in physical activity depends on adequate sleep. Conversely, 
sleep deprivation hinders attempts to lose weight through lifestyle 
measures,120 including adverse effects on appetite and overall 
wellbeing. Rather than being an ‘afterthought’ or even overlooked 
entirely, a focus on sleep sufficiency should be prioritized before in-
stituting other lifestyle measures such as dietary change.
To optimize sleep duration, there are useful strategies that include 
avoidance of blue light from screens during late evening, to allow nat-
ural melatonin release and the onset of sleepiness.121 Furthermore, it 
is necessary for the body to cool prior to sleep, therefore ensuring a 
cool bedroom is important. A focus on daily routines is also import-
ant, with avoidance of food and exercise in the hour before sleep, 
and ensuring physical activity during the day can also facilitate restful 
sleep.122 Finally, to improve sleep sufficiency on a population level will 
require some degree of cultural and societal change. This includes a 
collective re- discovery and appreciation for the value and importance 
of sleep for our overall health, productivity and wellbeing.
1.5.4  |  Mindfulness
Mindfulness is a state of being that enables a heightened aware-
ness of one's own internal emotions and immediate environs.123 
Ultimately, effective lifestyle change requires modified behaviour 
that in turn depends on mind- set and emotions. Although applica-
tion of mindfulness techniques could apply to any lifestyle meas-
ure, dietary change (including eating- related behaviour) is especially 
relevant. Multiple non- appetite- related factors influence our 
modern- day eating- related behaviour, including social norms and 
expectations, abundant food availability, food addiction and habitu-
alized meal times.124,125 Therefore, there is certainly a need to apply 
mindfulness techniques to eating- related behaviour.126
Our own group demonstrated proof of concept that application 
of mindfulness techniques (taught in groups as part of a hospital- 
based obesity management service) enables effective weight loss 
and adoption of healthy eating behaviours.123 Although this study 
did not focus exclusively on women with PCOS, there seems no rea-
son why our proof of concept data would not also apply to obese 
women with PCOS. This should be a focus for future research. In a 
further study, application of mindfulness techniques to overweight 
and obese participants also resulted in improved impulsive and binge 
eating behaviours with an additional benefit of improved physi-
cal activity, although interestingly no effects on body weight.127 
Finally, Shomaker and colleagues explored the implementation of 
a mindfulness- based intervention (MBI) compared to cognitive- 
behavioural therapy (CBT) in overweight and obese adolescent girls 
with symptoms of depression and at risk for the development of 
T2D. There were significant improvements in insulin resistance and 
depression in those girls randomized to MBI compared to those who 
received CBT. Given the similarity of this cohort to obese adolescent 
girls who develop PCOS, these data support a potential role for MBIs 
as a management strategy for PCOS.
There are many potential applications of mindfulness to the 
clinical management of PCOS. This includes the development and 
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maintenance of healthy lifestyle choices (including diet), but also as 
an expedient towards the establishment and maintenance of mental 
and emotional wellbeing, in the context of reproductive (including 
fertility) and hyperandrogenic disturbances. There are also many 
ways to teach our patients mindfulness techniques. Although formal 
one- to- one training in mindfulness may be beyond the remit of many 
healthcare settings currently within the NHS, virtual training ses-
sions for mindfulness are possible in the future. Furthermore, there 
are many opportunities for patients to self- teach mindfulness tech-
niques through various digital applications.
2  |  CONCLUSION
As the obesity epidemic ensues, and the global population contin-
ues to rise, it is likely that the prevalence of PCOS will also increase 
in the future. Given our genetic propensity for weight gain, and for 
the development of PCOS in some women, there seem to be two 
broad strategies on which to focus for the future prevention and 
management of PCOS: i) to change our genes (or, rather, modify gene 
expression); ii) to change our behaviour. A future potential strategy 
exists to manipulate, therapeutically, the expression of those genes 
that underlie a propensity for the development of PCOS, includ-
ing, for example, through epigenetic modification. Studies in animal 
models reveal that epigenetic changes may play a key role in medi-
ating the effects of lifestyle modification through dietary change, 
physical activity, attention to sleep quality and sufficiency and appli-
cation of techniques such as mindfulness. In our modern- day, busy, 
stressful, distracting and obesogenic environment, there is still much 
progress required in the development and successful application of 
lifestyle changes in women with PCOS, ultimately to facilitate effec-
tive loss and maintenance of body weight, but also to provide a basis 
on which to develop emotional wellbeing.
From the vantage point of dysfunctional insulin signalling, we 
can think of PCOS as a metabolic disorder. This perspective also 
provides a clear view of the role of weight gain and obesity in the 
pathogenesis of PCOS, through its effects on worsening aberrant 
insulin signalling by the PI3- K post- receptor pathway. Furthermore, 
the resultant compensatory hyperinsulinaemia, and its effects on 
the functional MAP- K post- receptor insulin pathway, provides an ex-
planation for the subsequent emergence of hyperandrogenism and 
reproductive dysfunction. The key role of abnormal insulin signalling 
provides insight into the central role of weight loss, and other factors 
that influence insulin sensitivity (such as improved sleep quality and 
sufficiency) in the effective management of women with PCOS.
Finally, having focused primarily on the complex pathogenic 
pathways that link weight gain and obesity with PCOS, we should 
never lose sight of the patient at the centre. Obesity is highly stig-
matized in our society. Hirsutism, acne and sub- fertility challenge 
key attributes of womanhood. The frequent clinical manifestation 
of PCOS during adolescence, a stage of life during which identity 
develops and vulnerability is prominent, only serves to heighten the 
potential for a negative impact of PCOS on the patient. Women and 
girls with obesity and PCOS require careful clinical management, 
administered with a compassionate and empathic approach, ideally 
from a multi- disciplinary specialist team, and with the patient placed 
at centre- stage.
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